Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Osteoporosis Reports
Erschienen in: Current Osteoporosis Reports 6/2018

05.10.2018 | Kidney and Bone (I Salusky and T Nickolas, Section Editors)

CKD-MBD: from the Pathogenesis to the Identification and Development of Potential Novel Therapeutic Targets

verfasst von: Rosilene Motta Elias, Maria Aparecida Dalboni, Ana Carolina E. Coelho, Rosa M. A. Moysés

Erschienen in: Current Osteoporosis Reports | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Although we have seen tremendous advances in the comprehension of CKD-MBD pathophysiology during the last few years, this was not accompanied by a significant change in mortality rate and quality of life. This review will address the traditional and updated pathophysiology of CKD-MBD along with the therapeutic limitations that affect CKD-MBD and proposed alternative treatment targets.

Recent Findings

An innovative concept brings the osteocyte to the center of CKD-MBD pathophysiology, in contrast to the traditional view of the skeleton as a target organ for disturbances in calcium, phosphate, parathyroid hormone, and vitamin D. Osteocytes, through the synthesis of FGF-23, sclerostin, among others, are able to interact with other organs, making bone an endocrine organ. Thus, osteocyte dysregulation might be an early event during the course of CKD.

Summary

This review will revisit general concepts on the pathophysiology of CKD-MBD and discuss new perspectives for its treatment.
Literatur
1.
Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765.PubMedPubMedCentral
2.
McQueen RB, Farahbakhshian S, Bell KF, Nair KV, Saseen JJ. Economic burden of comorbid chronic kidney disease and diabetes. J Med Econ. 2017;20(6):585–91.PubMed
3.
Wang V, Vilme H, Maciejewski ML, Boulware LE. The economic burden of chronic kidney disease and end-stage renal disease. Semin Nephrol. 2016;36(4):319–30.PubMed
4.
Penno G, Solini A, Bonora E, Orsi E, Fondelli C, Zerbini G, et al. Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study. Acta Diabetol. 2018;55(6):603–12.PubMed
5.
Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(6):572–86.PubMed
6.
Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945–53.PubMed
7.
Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–17.PubMed
8.
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18.PubMed
9.
Albright F, Bauer W, Cockrill JR, Ellsworth R. Studies on the physiology of the Parathyroid glands: II. The relation of the serum calcium to the serum phosphorus at different levels of parathyroid activity. J Clin Invest. 1931;9(4):659–77.PubMedPubMedCentral
10.
Liu SH, Chu HI. Treatment of renal osteodystrophy with dihydrotachysterol (A.T.10) and iron. Science. 1942;95(2467):388–9.PubMed
11.
Slatopolsky E. The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder. Kidney Int. 2011;79121:S3–8.PubMed
12.
Kuro OM. A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease. Kidney Int Suppl. 2013;3(5):420–6.
13.
• Tong A, Manns B, Hemmelgarn B, Wheeler DC, Evangelidis N, Tugwell P, et al. Establishing core outcome domains in hemodialysis: report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop. Am J Kidney Dis. 2017;69(1):97–107 This study shows a new approach driving clinical trials focusing in quality of life and survival, giving less importance to surrogate markers.PubMed
14.
Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26(2):229–38.PubMed
15.
Ferrari GO, Ferreira JC, Cavallari RT, Neves KR, dos Reis LM, Dominguez WV, et al. Mineral bone disorder in chronic kidney disease: head-to-head comparison of the 5/6 nephrectomy and adenine models. BMC Nephrol. 2014;15:69.PubMedPubMedCentral
16.
• Graciolli FG, Neves KR, Barreto F, Barreto DV, Dos Reis LM, Canziani ME, et al. The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease. Kidney Int. 2017;91(6):1436–46 This study reported the natural history of CKD-MBD as the renal function deteriorates. Authors showed the behavior of biochemical markers, as well as of osteocyte-related proteins.PubMed
17.
Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5(2):286–91.PubMedPubMedCentral
18.
Cancela AL, Oliveira RB, Graciolli FG, dos Reis LM, Barreto F, Barreto DV, et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract. 2011;117(1):c74–82.PubMed
19.
Sabbagh Y, Graciolli FG, O'Brien S, Tang W, dos Reis LM, Ryan S, et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012;27(8):1757–72.PubMed
20.
Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009;45(6):1161–8.PubMedPubMedCentral
21.
• Murali SK, Andrukhova O, Clinkenbeard EL, White KE, Erben RG. Excessive osteocytic Fgf23 secretion contributes to pyrophosphate accumulation and mineralization defect in hyp mice. PLoS Biol. 2016;14(4):e1002427 In this experimental research, it was demonstrated that FGF-23 inhibits bone mineralization through the inhibition of bone alkaline phosphatase.PubMedPubMedCentral
22.
Rhee Y, Bivi N, Farrow E, Lezcano V, Plotkin LI, White KE, et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone. 2011;49(4):636–43.PubMedPubMedCentral
23.
• Komaba H, Kaludjerovic J, Hu DZ, Nagano K, Amano K, Ide N, et al. Klotho expression in osteocytes regulates bone metabolism and controls bone formation. Kidney Int. 2017;92(3):599–611 Osteocyte-specific Klotho deletion leads to a unexpected improvement of bone formation. This effect is abrogated in CKD and hyperparathyroidism.PubMed
24.
• Carrillo-Lopez N, Panizo S, Alonso-Montes C, Roman-Garcia P, Rodriguez I, Martinez-Salgado C, et al. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int. 2016;90(1):77–89 Experimental study showing the local inhibitory effects of FGF-23 and Klotho on bone formation mediated by the increase of DKK1.PubMed
25.
Pereira RC, Juppner H, Gales B, Salusky IB, Wesseling-Perry K. Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients. PLoS One. 2015;10(3):e0120856.PubMedPubMedCentral
26.
Wesseling-Perry K. Osteocyte dysfunction and renal osteodystrophy: not just calcium and phosphorus anymore. Kidney Int. 2017;91(6):1276–8.PubMed
27.
• de Oliveira RA, Barreto FC, Mendes M, dos Reis LM, Castro JH, Britto ZM, et al. Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney Int. 2015;87(5):1039–45 First study to show the role of sclerotin causing adynamic bone disease in patients on peritoneal dialysis.PubMed
28.
Santos MFP, Hernandez MJ, de Oliveira IB, Siqueira FR, Dominguez WV, Dos Reis LM, et al. Comparison of clinical, biochemical and histomorphometric analysis of bone biopsies in dialysis patients with and without fractures. J Bone Miner Metab. 2018.
29.
Kanbay M, Solak Y, Siriopol D, Aslan G, Afsar B, Yazici D, et al. Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol. 2016;48(12):2029–42.PubMed
30.
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–27.PubMed
31.
Martola L, Barany P, Stenvinkel P. Why do dialysis patients develop a heart of stone and bone of China? Blood Purif. 2005;23(3):203–10.PubMed
32.
David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016;89(1):135–46.PubMedPubMedCentral
33.
• Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 2016;90(5):985–96 This study shows that FGF-23 synthesis not only is stimulated by inflammation, but can itself increase the synthesis of inflammatory cytokines by the hepatocytes.PubMedPubMedCentral
34.
Viaene L, Behets GJ, Heye S, Claes K, Monbaliu D, Pirenne J, et al. Inflammation and the bone-vascular axis in end-stage renal disease. Osteoporos Int. 2016;27(2):489–97.PubMed
35.
Christensen MH, Fenne IS, Nordbo Y, Varhaug JE, Nygard KO, Lien EA, et al. Novel inflammatory biomarkers in primary hyperparathyroidism. Eur J Endocrinol. 2015;173(1):9–17.PubMed
36.
Ben-awadh AN, Delgado-Calle J, Tu X, Kuhlenschmidt K, Allen MR, Plotkin LI, et al. Parathyroid hormone receptor signaling induces bone resorption in the adult skeleton by directly regulating the RANKL gene in osteocytes. Endocrinology. 2014;155(8):2797–809.PubMedPubMedCentral
37.
Young N, Mikhalkevich N, Yan Y, Chen D, Zheng WP. Differential regulation of osteoblast activity by Th cell subsets mediated by parathyroid hormone and IFN-gamma. J Immunol. 2005;175(12):8287–95.PubMedPubMedCentral
38.
•• Neale Weitzmann M, Pacifici R. Parathyroid diseases and T cells. Curr Osteoporos Rep. 2017;15(3):135–41 This review highlights the actions of T-cell on PTH-induced bone resorption, reinforcing the link between hyperparathyroidism, inflammation and bone loss.PubMedPubMedCentral
39.
Tawfeek H, Bedi B, Li JY, Adams J, Kobayashi T, Weitzmann MN, et al. Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PloS One. 2010;5(8):e12290.PubMedPubMedCentral
40.
Maung SC, El Sara A, Chapman C, Cohen D, Cukor D. Sleep disorders and chronic kidney disease. World J Nephrol. 2016;5(3):224–32.PubMedPubMedCentral
41.
Elias RM, Chan CT, Bradley TD. Altered sleep structure in patients with end-stage renal disease. Sleep Med. 2016;20:67–71.PubMed
42.
Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. 2011;32(12):1484–92.PubMed
43.
Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006–14.PubMedPubMedCentral
44.
Huang HC, Walters G, Talaulikar G, Figurski D, Carroll A, Hurwitz M, et al. Sleep apnea prevalence in chronic kidney disease - association with total body water and symptoms. BMC Nephrol. 2017;18(1):125.PubMedPubMedCentral
45.
Adams RJ, Appleton SL, Vakulin A, Hanly PJ, McDonald SP, Martin SA, et al. Chronic kidney disease and sleep apnea association of kidney disease with obstructive sleep apnea in a population study of men. Sleep. 2017;40(1).
46.
Drager LF, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest. 2011;140(2):534–42.PubMedPubMedCentral
47.
Jenner R, Lorenzi-Filho G, Drager LF. Cardiovascular impact of obstructive sleep apnea: does gender matter? Expert Rev Cardiovasc Ther. 2014;12(3):281–3.PubMed
48.
Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58(5):811–7.PubMed
49.
Elias RM, Bradley TD, Kasai T, Motwani SS, Chan CT. Rostral overnight fluid shift in end-stage renal disease: relationship with obstructive sleep apnea. Nephrol Dial Transplant. 2012;27(4):1569–73.PubMed
50.
• Stockings vs. continuous positive airway pressure on overnight fluid shift and obstructive sleep apnea among patients on hemodialysis. Frontiers in medicine. 2017;4:57. Authors show an improvement of sleep apnea by appliyng compression stockings in patients on hemodialysis.
51.
Hirai T, Tanaka K, Togari A. Beta-adrenergic receptor signaling regulates Ptgs2 by driving circadian gene expression in osteoblasts. J Cell Sci. 2014;127(Pt 17):3711–9.PubMed
52.
Fujihara Y, Kondo H, Noguchi T, Togari A. Glucocorticoids mediate circadian timing in peripheral osteoclasts resulting in the circadian expression rhythm of osteoclast-related genes. Bone. 2014;61:1–9.PubMed
53.
Guner I, Uzun DD, Yaman MO, Genc H, Gelisgen R, Korkmaz GG, et al. The effect of chronic long-term intermittent hypobaric hypoxia on bone mineral density in rats: role of nitric oxide. Biol Trace Elem Res. 2013;154(2):262–7.PubMed
54.
Chen G, Chen L, Wen J, Yao J, Li L, Lin L, et al. Associations between sleep duration, daytime nap duration, and osteoporosis vary by sex, menopause, and sleep quality. J Clin Endocrinol Metab. 2014;99(8):2869–77.PubMed
55.
Kobayashi D, Takahashi O, Deshpande GA, Shimbo T, Fukui T. Association between osteoporosis and sleep duration in healthy middle-aged and elderly adults: a large-scale, cross-sectional study in Japan. Sleep Breathing. 2012;16(2):579–83.PubMed
56.
Fu X, Zhao X, Lu H, Jiang F, Ma X, Zhu S. Association between sleep duration and bone mineral density in Chinese women. Bone. 2011;49(5):1062–6.PubMed
57.
Everson CA, Folley AE, Toth JM. Chronically inadequate sleep results in abnormal bone formation and abnormal bone marrow in rats. Exp Biol Med. 2012;237(9):1101–9.
58.
Casazza K, Hanks LJ, Fernandez JR. Shorter sleep may be a risk factor for impaired bone mass accrual in childhood. J Clin Densitom. 2011;14(4):453–7.PubMedPubMedCentral
59.
Sforza E, Thomas T, Barthelemy JC, Collet P, Roche F. Obstructive sleep apnea is associated with preserved bone mineral density in healthy elderly subjects. Sleep. 2013;36(10):1509–15.PubMedPubMedCentral
60.
Torres M, Montserrat JM, Pavia J, Dalmases M, Ros D, Fernandez Y, et al. Chronic intermittent hypoxia preserves bone density in a mouse model of sleep apnea. Respir Physiol Neurobiol. 2013;189(3):646–8.PubMed
61.
Mariani S, Fiore D, Varone L, Basciani S, Persichetti A, Watanabe M, et al. Obstructive sleep apnea and bone mineral density in obese patients. Diabetes Metab Syndr Obes. 2012;5:395–401.PubMedPubMedCentral
62.
Uzkeser H, Yildirim K, Aktan B, Karatay S, Kaynar H, Araz O, et al. Bone mineral density in patients with obstructive sleep apnea syndrome. Sleep Breath. 2013;17(1):339–42.PubMed
63.
Takaki J, Nishi T, Nangaku M, Shimoyama H, Inada T, Matsuyama N, et al. Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis. Am J Kidney dis. 2003;41(4):833–9.PubMed
64.
Wali S, Shukr A, Boudal A, Alsaiari A, Krayem A. The effect of vitamin D supplements on the severity of restless legs syndrome. Sleep Breath. 2015;19(2):579–83.PubMed
65.
Neves PD, Graciolli FG, Oliveira IB, Bridi RA, Moyses RM, Elias RM. Effect of mineral and bone metabolism on restless legs syndrome in hemodialysis patients. J Clin Sleep Med. 2017;13(1):89–94.PubMedPubMedCentral
66.
Hruska KA, Sugatani T, Agapova O, Fang Y. The chronic kidney disease - mineral bone disorder (CKD-MBD): advances in pathophysiology. Bone. 2017;100:80–6.PubMedPubMedCentral
67.
Metzinger-Le Meuth V, Burtey S, Maitrias P, Massy ZA, Metzinger L. microRNAs in the pathophysiology of CKD-MBD: biomarkers and innovative drugs. Biochim Biophys Acta. 2017;1863(1):337–45.
68.
Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M, et al. Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism. Clin J Am Soc. 2015;10(6):1021–30.
69.
Goldenstein PT, Elias RM, Pires de Freitas do Carmo L, Coelho FO, Magalhaes LP, Antunes GL, et al. Parathyroidectomy improves survival in patients with severe hyperparathyroidism: a comparative study. PloS One. 2013;8(8):e68870.PubMedPubMedCentral
70.
Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2018;13(6):952–61.PubMed
71.
Karakose M, Caliskan M, Arslan MS, Demirci T, Karakose S, Cakal E. The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism. Endocrine. 2017;55(1):283–8.PubMed
72.
Santos RS, Coelho FM, Silva BC, Graciolli FG, Dominguez WV, Menezes Montenegro FL, et al. Parathyroidectomy improves restless leg syndrome in patients on hemodialysis. PLoS One. 2016;11(5):e0155835.PubMedPubMedCentral
73.
Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36.PubMed
74.
Steller Wagner Martins C, Jorgetti V, Moyses RMA. Time to rethink the use of bone biopsy to prevent fractures in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2018;27(4):243–50.PubMed
75.
Isakova T, Anderson CA, Leonard MB, Xie D, Gutierrez OM, Rosen LK, et al. Diuretics, calciuria and secondary hyperparathyroidism in the chronic renal insufficiency cohort. Nephrol Dial Transplant. 2011;26(4):1258–65.PubMedPubMedCentral
76.
• Vasco RF, Moyses RM, Zatz R, Elias RM. Furosemide increases the risk of hyperparathyroidism in chronic kidney disease. Am J Nephrol. 2016;43(6):421–30 The role of diuretic in CKD-MBD was the main focus in this study showing and increased risk of hyperparathyroidism with furosemide. PubMed
77.
Elias RM, Moyses RMA. Elderly patients with chronic kidney disease have higher risk of hyperparathyroidism. Int Urol Nephrol. 2017;49(10):1815–21.PubMed
78.
Vasco RFV, Reis ET, Moyses RMA, Elias RM. Thiazide increases serum calcium in anuric patients: the role of parathyroid hormone. Arch Osteoporos. 2017;12(1):31.PubMed
79.
Koppel MH, Massry SG, Shinaberger JH, Hartenbower DL, Coburn JW. Thiazide-induced rise in serum calcium and magnesium in patients on maintenance hemodialysis. Ann Intern Med. 1970;72(6):895–901.PubMed
80.
Dvorak MM, De Joussineau C, Carter DH, Pisitkun T, Knepper MA, Gamba G, et al. Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone. J Am Soc Nephrol. 2007;18(9):2509–16.PubMedPubMedCentral
81.
Brauer M, Frei E, Claes L, Grissmer S, Jager H. Influence of K-Cl cotransporter activity on activation of volume-sensitive Cl- channels in human osteoblasts. Am J Physiol Cell Physiol. 2003;285(1):C22–30.PubMed
82.
Kim CH, Kim SW, Kim GS. Effects of hydrochlorothiazide and furosemide diuretics on human bone marrow stromal osteoprogenitor cells. Metab Clin Exp. 2000;49(1):17–21.PubMed
83.
Berry SD, Zhu Y, Choi H, Kiel DP, Zhang Y. Diuretic initiation and the acute risk of hip fracture. Osteoporos Int. 2013;24(2):689–95.PubMed
84.
Muller ME, Forni Ogna V, Maillard M, Stoudmann C, Zweiacker C, Anex C, et al. Furosemide stimulation of parathormone in humans: role of the calcium-sensing receptor and the renin-angiotensin system. Pflugers Arch – Eur J Physiol. 2015;467(12):2413–21.
85.
Zhou X, Chen K, Lei H, Sun Z. Klotho gene deficiency causes salt-sensitive hypertension via monocyte chemotactic protein-1/CC chemokine receptor 2-mediated inflammation. J Am Soc Nephrol. 2015;26(1):121–32.PubMed
Metadaten
Titel
CKD-MBD: from the Pathogenesis to the Identification and Development of Potential Novel Therapeutic Targets
verfasst von
Rosilene Motta Elias
Maria Aparecida Dalboni
Ana Carolina E. Coelho
Rosa M. A. Moysés
Publikationsdatum
05.10.2018
Verlag
Springer US
Erschienen in
Current Osteoporosis Reports / Ausgabe 6/2018
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-018-0486-0

Weitere Artikel der Ausgabe 6/2018

Current Osteoporosis Reports 6/2018 Zur Ausgabe

Biomechanics (G Niebur and J Wallace, Section Editors)

In Vivo Osteocyte Mechanotransduction: Recent Developments and Future Directions

Cancer-induced Musculoskeletal Diseases (J Sterling and E Keller, Section Editors)

Crosstalk Between Sensory Nerves and Cancer in Bone

Epidemiology and Pathophysiology (F Cosman and D Shoback, Section Editors)

Importance of Recent Fracture as Predictor of Imminent Fracture Risk

Bone and Joint Pain (T King and S Amin, Section Editors)

Celiac Disease—Musculoskeletal Manifestations and Mechanisms in Children to Adults

Kidney and Bone (I Salusky and T Nickolas, Section Editors)

Mineral and Bone Disease in Kidney Transplant Recipients

Invited Commentary

Fibula: The Forgotten Bone—May It Provide Some Insight On a Wider Scope for Bone Mechanostat Control?

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise